In this Issue:
Management of cancer of unknown primary site
Presurgical assessment of CRCLM
Lymph node staging in resectable gastric cancer
Mutational status in mCRC matters in treatment regimens
GCC in LNs and tumour recurrence in stage II colon cancer
Combined molecular blockade in pre-treated mCRC
Phosphorylated PP2A: a potential target in mCRC?
FOLFIRI + cetuximab first-line in stage IV CRC?
p53MVA therapy in refractory GI malignancies
Masitinib: benefits in imatinib-resistant GIST
Please login below to download this issue (PDF)